

Global consultation on SARS-CoV-2 variants of concern and their impact on public health interventions

10 June 2021, 13:00 - 16:30 CEST

Zoom (Please register in advance [here](#))

Tentative agenda

TIME	TOPIC	SPEAKERS
13:00-13:05	Opening remarks	Mike Ryan, WHO
13:05-13:10	Updates on the WHO global risk monitoring and assessment framework for SARS-CoV-2 variants	Sylvie Briand, WHO
SESSION 1: FOCUS ON SARS-COV-2 VARIANTS		
13:10-14:10	Update on VOI/VOC designation process and naming system	Lorenzo Subissi, WHO
	Global epidemiological situation with SARS-CoV-2 variants	Brett Archer, WHO
	Risk assessing SARS-CoV-2 variants	Wendy Barclay, Imperial College London
	<i>Moderator: Maria Van Kerkhove, WHO</i>	
SESSION 2: EVIDENCE FRAMEWORK FOR VARIANTS & COVID-19 VACCINES		
14:10-15:20	Topics: <ul style="list-style-type: none"> Decision-making process and methods to decide if a modified vaccine or a new vaccine is needed (10 mins) Review and critical appraisal of randomized evidence on vaccines and variants (10 mins) Review and critical appraisal of non-randomized evidence on vaccines and variants (10 mins) Developers' corner – current data and plans for evaluation of the effect of variants on vaccine efficacy/effectiveness (20 mins) 	Philip Krause, Chairperson, WHO research expert group on COVID-19 vaccines Isabelle Boutron Université de Paris Julian Higgins University of Bristol Randall N Hyer, Moderna Philip Dormitzer, Pfizer Rabun Mallory, Novavax

Steven Gong, Clover
 Biopharmaceuticals
 Allen Lien, Medigen Vaccine
 Biologics Corp
 Raches Ella, Bharat Biotech
 Robert Coleman, Codagenix
 Pune Pitisuttithum, Mahidol
 University
 Trina Racine, Vaccine and
 Infectious Disease Org.
 (VIDO)
 Luigi Aurisicchio,
 Takis/Rottapharm Biotech
 Christine Roberts
 GeneOne Life Science, Inc

- Preliminary considerations of other epidemiological data to inform decisions (20 mins)

Panel discussion
 Helen Rees, Wits RHI,
 University of Witwatersrand

Mary Ramsay, Immunization,
 Hepatitis, and Blood Safety
 department, Public Health
 England | HPA

John Peter Figueroa,
 University of the West Indies,
 Jamaica

Moderator: Kanta Subbarao

David Wentworth, Virology
 surveillance and diagnosis
 branch, Influenza Division,
 NCIRD, US CDC

SESSION 3: IMPACT ON PUBLIC HEALTH DECISION-MAKING

15:20-15:50 Perspectives of regulators and developers for variants and COVID-19 vaccines

Moderator: Marco Cavaleri, EMA

Chang-Joon Bae, MFDS
 Marco Cavaleri, EMA
 Adam Hacker, CEPI
 Philip Krause, FDA

15:50-16:20 Impact of variants on public health decision-making:

- Global perspective
- Country level perspectives

Moderator: Nyka Alexander, WHO

Hanna Nohynek, SAGE
 Christine Carrington,
 Trinidad & Tobago
 Nazeem Muhajarine,
 CoVaRR-Net

16:20-16:30 Concluding remarks

Jaouad Mahjour, WHO